| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | 0.079 | 0.2 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.062 | 0.2 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.2 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | Fumonisin B1 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |